Short Interest in Oragenics, Inc. (NYSEAMERICAN:OGEN) Increases By 303.6%

Oragenics, Inc. (NYSEAMERICAN:OGEN) was the recipient of a large increase in short interest during the month of December. As of December 15th, there was short interest totaling 139,273 shares, an increase of 303.6% from the November 30th total of 34,508 shares. Currently, 3.7% of the company’s shares are sold short. Based on an average daily volume of 114,186 shares, the days-to-cover ratio is presently 1.2 days. Based on an average daily volume of 114,186 shares, the days-to-cover ratio is presently 1.2 days. Currently, 3.7% of the company’s shares are sold short.

Hedge Funds Weigh In On Oragenics

Several institutional investors have recently made changes to their positions in OGEN. Bank of America Corp DE raised its holdings in shares of Oragenics by 7,374.0% in the second quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock valued at $59,000 after acquiring an additional 15,338 shares in the last quarter. Sabby Management LLC bought a new position in Oragenics during the 3rd quarter worth about $77,000. Finally, Clear Street LLC purchased a new position in Oragenics during the 2nd quarter valued at about $270,000. Hedge funds and other institutional investors own 18.71% of the company’s stock.

Oragenics Price Performance

Shares of NYSEAMERICAN:OGEN traded up $0.01 on Thursday, hitting $0.84. 34,268 shares of the company’s stock were exchanged, compared to its average volume of 83,795. The business’s 50 day simple moving average is $1.05 and its two-hundred day simple moving average is $1.50. The stock has a market capitalization of $3.48 million, a price-to-earnings ratio of -0.07 and a beta of 0.92. Oragenics has a 12 month low of $0.82 and a 12 month high of $18.90.

Oragenics (NYSEAMERICAN:OGEN) last posted its quarterly earnings results on Friday, November 7th. The company reported ($1.96) EPS for the quarter.

Oragenics Company Profile

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.